Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Retlirafusp Alfa in Combination With SOX and Intraperitoneal Nab-Paclitaxel as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma With Malignant Ascites

NCT07855757 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT07855757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07855757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Retlirafusp Alfa in Combination With SOX and Intraperitoneal Nab-Paclitaxel as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma With Malignant Ascites
Lead sponsor
Zhejiang Cancer Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
June 1, 2026
Completion date
June 30, 2028
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ascites, malignant, gastric cancer (gc), peritoneal metastases from gastric cancer